Note, these publications refer to the legacy name of our technology, now branded and trademarked as Celletto™
Basilard Biotech, Inc. announces the premiere of their new HD animation video introducing SoloPore™, their novel, IP protected, a disruptive technology platform for ex-vivo cell and gene delivery.
Solopore™ is a new, better, nanomechanical cell transfection approach that outperforms the prevailing non-viral approaches (like electroporation) and mitigates the…
Read More
Basilard BioTech, Inc. announces a second $250K pre-seed investment (total now $500k) from Palo Alto based Vertical Venture Partners (VVP).
It follows only 6 weeks after VVP’s first investment meant to accelerate the commercialization of Basilard BioTech’s next generation nanomechanical…
Read More